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The Editorial on the Research Topic 
The CXCR4 Ligand/Receptor Family and the DPP4 Protease in High-Risk Cardiovascular 
Patients
Cardiovascular disease (CVD) is the most common cause of morbidity and mortality worldwide 
and was responsible for 17.5 million deaths in 2012. This equals 31% of all deaths globally and is 
almost double the amount of cancer-related deaths (1). Although CVD encompasses a broad range 
of pathologic conditions, 80% of all CVD-related deaths are due to heart attacks and stroke (1). 
An important underlying pathology is atherosclerosis, a chronic inflammatory state of the arterial 
wall that is characterized by lipid deposition, dysfunction of the endothelium, and infiltration of 
inflammatory cells into the vessel wall, resulting in the development of atherosclerotic lesions (2).
Type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) have been identified as 
important risk factors for CVD. Fifty percent of patients with CKD stages 4–5 suffer from CVD (3), 
and cardiovascular mortality accounts for ~40–50% of all deaths in these patients, compared with 
26% in controls with normal kidney function (4, 5). Also in patients with diabetes, CVD accounts 
for at least 50% of deaths (6). With currently around 10–13% of people presenting with CKD and 
more than 8% of adults suffering from diabetes (6–8), the social and economic burden of diabetes, 
CKD, and CVD is extremely high. Thus, a better understanding of the mechanisms contributing to 
and mediating the interplay between T2DM, CKD, and CVD is required to improve the prevention 
and treatment of these diseases.
In this Research Topic, we focus on the classical CXC chemokine receptor CXCR4 (9), its 
cognate ligand CXCL12 (10), and the chemokine-like cytokine macrophage migration inhibitory 
factor (MIF), which functions as a non-cognate ligand of CXCR4 (11), in the context of CVD. 
An emphasis is made on links with T2DM and CKD. Also, we discuss dipeptidyl peptidase-4 
(DPP4) as an important protease known to destabilize CXCL12 and thus to influence signaling 
through the CXCL12/CXCR4 axis. Chemokines and their receptors are important mediators of 
cell mobilization, recruitment and arrest, and additionally more broadly induce cell activation by 
triggering various intracellular signaling tracks. Chemokines control basic homeostatic condi-
tions but are also critically involved in inflammatory processes, e.g., in atherosclerosis (12, 13). 
Genome-wide association studies revealed single nucleotide polymorphisms connecting CXCL12 
as well as MIF with CVD (2, 14–19), and a role for both of these mediators in T2DM and CKD 
has been reported. In this Research Topic, we introduce the reader to the comorbidities T2DM 
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and CKD and their connection with CVD, and provide up-to-
date information on the involvement of CXCL12/MIF/CXCR4 
and DPP4 in each of these pathologies. One focus is laid upon 
providing insight on mechanistic level.
t2dM, CKd, aNd CVd: CoMorBiditiES 
iNtErliNKEd oN MECHaNiStiC lEVEl
There is clear-cut epidemiologic evidence linking the comorbidi-
ties T2DM and CKD with CVD. Progress has also been made to 
explain the comorbid status of these diseases on molecular level; 
however, the interaction seems highly complex and insight into 
the connecting mechanisms is mostly still in its infancy. Here, 
Schuett et al. (Germany) present an overview of the inflamma-
tory processes underlying atherosclerosis and highlight the role 
of inflammation in T2DM and chronic inflammatory diseases in 
relation to CVD. The current prevalence and incidence of T2DM, 
CKD, and CVD are summarized by Gajjala et al. (Germany). They 
also provide insight into molecular mechanisms interconnecting 
these comorbidities.
Animal models allow us to investigate these interconnecting 
mechanisms in more detail and enable us to evaluate potential 
therapeutic strategies. Hewitson et  al. (Australia) summarize 
available animal models for investigating mutual interactions 
between cardiac and renal injury and critically discuss how 
representative they are for human disease. This also includes 
an overview of animal models for hypertension, diabetes, and 
obesity, which are linked with kidney and cardiac injury through 
systemic alterations.
tHE CXCr4 CHEMoKiNE rECEPtor 
aNd itS liGaNdS CXCl12 aNd MiF: 
MolECUlar aSPECtS aNd 
iNVolVEMENt iN CVd, t2dM, aNd CKd
Pawig et  al. (Germany) present the diversity and interconnec-
tions in the CXCR4 receptor/ligand family. Signaling pathways 
initiated by binding of CXCL12 vs. MIF to CXCR4 are discussed, 
and it is elaborated on how ACKR3 (previously called CXCR7) 
affects CXCR4 signaling. Finally, authors summarize the (patho)
biological functions of CXCR4 signaling mediated by CXCL12 
or MIF that are likely to be important in devising potential future 
therapies targeting this signaling axis.
van der Vorst et al. (Germany) present an overview of the role 
of CXCL12 vs. MIF in CVD, highlighting the differences and 
similarities. Vidakovic et  al. (Serbia) discuss the controversial 
role of the CXCL12/CXCR4 axis in diabetes, whereas Morrison 
and Kleemann (The Netherlands) summarize the role of MIF in 
obesity, insulin resistance, T2DM, and associated hepatic comor-
bidities as revealed by both human and animal studies. Bruchfeld 
(Sweden) discusses MIF in the context of kidney disease, while 
complementarily, Valiño-Rivas et  al. (Spain) elaborate on the 
expression and role of CD74, an additional receptor for MIF and 
the MIF homolog MIF-2 (or D-DT) in kidney injury.
dPP4 aS rEGUlator oF CXCl12 aNd 
itS iNVolVEMENt iN CVd, t2dM, 
aNd CKd
DPP4 (also known as CD26) is known to destabilize CXCL12. 
Therefore, our Research Topic also addresses molecular 
aspects and functions of this protease as well as its role in 
CVD, T2DM, and CKD. Waumans et  al. (Belgium) provide a 
comprehensive insight into DPP4 and its role in the immune 
system and inflammatory diseases including atherosclerosis. 
This also includes an overview of other family members of the 
dipeptidyl peptidase family as well as of prolyl oligopeptidases 
and prolyl carboxypeptidases. Circulating DPP4 is increased in 
patients with T2DM, and DPP4 inhibition is used for treatment 
of T2DM. Thus, Röhrborn et  al. (Germany) provide detailed 
insight into the expression, enzymatic activity, and function of 
DPP4 in the context of diabetes, based on in vitro, animal, and 
human studies. Also, mechanistic insight into the role of DPP4 
in the T2DM-associated morbidities CVD and liver disease is 
provided. The role of DPP4 and its regulation of the CXCL12/
CXCR4 axis in CVD are then discussed in more detail by Zhong 
and Rajagopalan (USA). Finally, Panchapakesan and Pollock 
(Australia) summarize potential renoprotective effects of DPP4 
inhibitors in diabetic kidney disease and also discuss the cardio-
vascular safety profile of DPP4 inhibitors.
Altogether, this Research Topic aims to assist both special-
ists and interested non-specialists and to stimulate further 
initiatives to unravel the mechanistic involvement of the 
CXCR4 ligand/receptor family in the detrimental interplay 
between the comorbidities T2DM, CKD, and CVD, poten-
tially paving the way for new therapeutic initiatives in the 
future.
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